TY - JOUR
T1 - Mycobacterium abscessus and massiliense lung infection during macrolide treatment for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation
AU - Miyake, Noriko
AU - Chong, Yong
AU - Nishida, Ruriko
AU - Takenaka, Katsuto
AU - Kato, Koji
AU - Miyamoto, Toshihiro
AU - Aono, Akio
AU - Takaki, Akiko
AU - Mitarai, Satoshi
AU - Shimoda, Shinji
AU - Shimono, Nobuyuki
AU - Akashi, Koichi
N1 - Publisher Copyright:
© 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases
PY - 2018/1
Y1 - 2018/1
N2 - In patients undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT), post-transplant lung infection is critical for their prognosis. Mycobacterium abscessus complex is not fully recognized as a nontuberculous mycobacteria (NTM) pathogen of post-SCT lung infection. Here, we present three post-allogeneic SCT patients who developed pulmonary infection caused by M. abscessus complex including M. abscessus and M. massiliense. In all three cases, macrolide antibiotics had been administered for bronchiolitis obliterans syndrome (BOS) before the confirmation of their infection, and macrolide resistance was noted in the M. abscessus isolates, one of which resulted in an unfavorable treatment outcome. It is important to consider M. abscessus lung infection as well as other NTM in patients receiving allo-SCT, particularly those receiving macrolide therapy for BOS.
AB - In patients undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT), post-transplant lung infection is critical for their prognosis. Mycobacterium abscessus complex is not fully recognized as a nontuberculous mycobacteria (NTM) pathogen of post-SCT lung infection. Here, we present three post-allogeneic SCT patients who developed pulmonary infection caused by M. abscessus complex including M. abscessus and M. massiliense. In all three cases, macrolide antibiotics had been administered for bronchiolitis obliterans syndrome (BOS) before the confirmation of their infection, and macrolide resistance was noted in the M. abscessus isolates, one of which resulted in an unfavorable treatment outcome. It is important to consider M. abscessus lung infection as well as other NTM in patients receiving allo-SCT, particularly those receiving macrolide therapy for BOS.
UR - http://www.scopus.com/inward/record.url?scp=85030755186&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030755186&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2017.08.011
DO - 10.1016/j.jiac.2017.08.011
M3 - Article
C2 - 28988958
AN - SCOPUS:85030755186
SN - 1341-321X
VL - 24
SP - 78
EP - 81
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 1
ER -